How should acquired trisomy 14 be evaluated and managed?

Acquired Trisomy 14: Evaluation and Management

Acquired trisomy 14 should be evaluated with G-banded chromosome analysis as the first-line test on bone marrow specimens, recognizing this as a rare, non-random cytogenetic abnormality associated with myeloid neoplasms, particularly myelodysplastic syndromes (MDS) in elderly males.

Clinical Context and Significance

Acquired trisomy 14 represents a heterogeneous group of myeloid neoplasms that predominantly affects older patients (median age 71-77 years) with marked male predominance (82%) 1, 2. This abnormality is associated with:

• MDS (44% of cases) - most common presentation
• MDS/MPN overlap syndromes (31%)
• Acute myeloid leukemia (25%)
• Multilineage dysplasia is present in virtually all cases 1

Critical distinction: Trisomy 14 differs from trisomy 8 in that it is NOT considered MDS-defining by WHO/ICC classifications in the absence of morphologic dysplasia 3. This means you cannot diagnose MDS based solely on finding trisomy 14.

Diagnostic Algorithm

Initial Testing Strategy

1. G-banded chromosome analysis on bone marrow - this is the recommended first-line test 3

   • Bone marrow is the preferred specimen
   • Analyze minimum 20 metaphases if no abnormality detected
   • If trisomy 14 found, minimum 10 metaphases sufficient for characterization
   • Note: Trisomy 14 is often present as a mosaic cell line (8/11 cases in one series) 2

2. If chromosome analysis incomplete/unsuccessful: Proceed to chromosomal microarray (CMA) or FISH panel 3

   • CMA particularly useful for detecting clonal copy number alterations and copy-neutral loss of heterozygosity
   • Can identify concurrent TP53 abnormalities that define specific MDS subcategories

3. Concurrent molecular testing: Next-generation sequencing for recurrent somatic mutations 3

   • Oncogenic mutations in proliferation/survival genes are RARE in isolated trisomy 14 1
   • However, testing helps distinguish from clonal hematopoiesis of indeterminate potential (CHIP)
   • TP53 mutation testing is particularly important if TP53 deletion detected

Key Morphologic Features to Document

• Multilineage dysplasia - present in all cases 1
• Abnormal red cell morphology - elliptocytes and/or schistocytes observed in majority of cases 2
• Blast percentage - determines disease classification (MDS vs AML)

Prognostic Implications

Survival data: Patients with MDS and isolated trisomy 14 demonstrate similar overall survival and leukemia transformation rates compared to MDS with diploid karyotype 1. Reported survival ranges from 1 month to approximately 3 years 2.

The IPSS-R cytogenetic risk stratification system does not specifically list trisomy 14 among the defining abnormalities, unlike trisomy 8, +19, or other recurrent changes 3. This suggests intermediate prognostic significance.

Management Approach

1. Confirm clonality: Ensure trisomy 14 meets ISCN criteria (present in ≥2 metaphases for gains) 4

2. Establish definitive diagnosis: Integrate cytogenetic findings with:

   • Bone marrow morphology and blast count
   • Complete blood count and peripheral smear
   • Molecular testing results
   • Clinical presentation

3. Risk stratification: Apply IPSS-R scoring incorporating:

   • Cytogenetic findings (though trisomy 14 not specifically categorized)
   • Blast percentage
   • Cytopenias
   • Molecular mutations if present

4. Baseline FISH for monitoring: Consider establishing FISH probe for chromosome 14 to track clonal burden during follow-up 3

Critical Pitfalls to Avoid

• Do not diagnose MDS based solely on trisomy 14 - morphologic dysplasia must be present 3
• Analyze cells of varying quality - neoplastic metaphases often have poor morphology; don't exclude suboptimal cells 4
• Screen for isochromosome 14q - present in 4/11 cases in one series 2
• Distinguish from constitutional mosaicism - acquired trisomy 14 in adults is distinct from prenatal/constitutional findings 5, 6, 7
• Check for concurrent clones - mosaic patterns common, may have clonal evolution 4, 1, 2

Follow-Up Strategy

For patients with documented trisomy 14 at diagnosis:

• Repeat chromosome analysis at follow-up
• Analyze/score minimum 20 metaphases if normal result obtained
• If abnormal clone persists, minimum 10 metaphases sufficient 4
• Consider quantitative molecular methods (RQ-PCR, flow cytometry) for minimal residual disease monitoring when available 4